John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial

2018 Genitourinary Cancers Symposium
Tweet this page

John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radiation plus gemcitabine for patients with muscle-invasive bladder cancer (Abstract 408).

Advertisement

Advertisement



Advertisement